Monopar Therapeutics Inc (MNPR)

$0.72

+0.06

(+9.92%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.64
    $0.73
    $0.72
    downward going graph

    11.11%

    Downside

    Day's Volatility :12.33%

    Upside

    1.37%

    downward going graph
  • $0.27
    $1.73
    $0.72
    downward going graph

    61.96%

    Downside

    52 Weeks Volatility :84.17%

    Upside

    58.38%

    downward going graph

Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
-0.49%
0.0%
6 Months
80.09%
0.0%
1 Year
-10.27%
0.0%
3 Years
-87.96%
-20.2%

Highlights

Market Capitalization
11.3M
Book Value
$0.43
Earnings Per Share (EPS)
-0.52
Wall Street Target Price
2.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-48.38%
Return On Equity TTM
-92.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.36
EPS Estimate Next Year
-0.32
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Monopar Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
7
Hold
1
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 223.61%

Current $0.72
Target $2.33

Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc
Monopar Therapeutics Inc
-12.14%
80.09%
-10.27%
-87.96%
-97.53%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc
Monopar Therapeutics Inc
NA
NA
NA
-0.36
-0.93
-0.48
NA
0.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Buy
$11.3M
-97.53%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Monopar Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 71.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 274.5%

Institutional Holdings

  • Millennium Management LLC

    1.10%

  • Vanguard Group Inc

    0.26%

  • Geode Capital Management, LLC

    0.24%

  • HRT FINANCIAL LLC

    0.18%

  • Gerber LLC

    0.16%

  • Virtu Financial LLC

    0.14%

Company Information

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.

Organization
Monopar Therapeutics Inc
Employees
9
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Industry
Health Technology

Discover More

FAQs